Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Innoviva, Inc. - Common Stock
(NQ:
INVA
)
19.58
-0.07 (-0.36%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innoviva, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
↗
January 08, 2026
Via
MarketBeat
Get insights into the top gainers and losers of Tuesday's after-hours session.
↗
December 16, 2025
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
December 12, 2025
From
Innoviva, Inc.
Via
Business Wire
Beyond The Numbers: 5 Analysts Discuss Innoviva Stock
↗
September 30, 2025
Via
Benzinga
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
December 11, 2025
From
Innoviva, Inc.
Via
Business Wire
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
November 25, 2025
From
Innoviva, Inc.
Via
Business Wire
Stay updated with the stocks that are on the move in today's pre-market session.
↗
November 13, 2025
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via
Chartmill
Value Investing Case Study: INNOVIVA INC (NASDAQ:INVA)
↗
November 11, 2025
Discover Innoviva (INVA), a potential value stock with strong fundamentals. Its attractive valuation, healthy balance sheet, and solid profitability suggest it trades below intrinsic worth.
Via
Chartmill
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
November 05, 2025
From
Innoviva, Inc.
Via
Business Wire
Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
October 20, 2025
From
Innoviva Specialty Therapeutics
Via
Business Wire
Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025
October 07, 2025
From
Innoviva Specialty Therapeutics
Via
Business Wire
Innoviva Inc (NASDAQ:INVA): A Prime Candidate for Value Investors Seeking Undervalued Stocks
↗
September 08, 2025
Discover Innoviva (INVA), a value stock with strong fundamentals. It trades below intrinsic value, boasts a healthy balance sheet, and has promising growth prospects in biopharma.
Via
Chartmill
Innoviva to Participate in Upcoming Investor Conferences
August 26, 2025
From
Innoviva, Inc.
Via
Business Wire
Innoviva Inc (NASDAQ:INVA) Recognized as a "Decent Value" Stock with Strong Valuation and Growth Potential
↗
August 18, 2025
Innoviva (INVA) is a value stock with strong valuation metrics, solid financial health, and growth potential, making it an attractive pick for value investors.
Via
Chartmill
Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award
August 13, 2025
From
Innoviva Specialty Therapeutics, Inc.
Via
Business Wire
Expert Outlook: Innoviva Through The Eyes Of 4 Analysts
↗
August 11, 2025
Via
Benzinga
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday
↗
August 11, 2025
Via
Benzinga
Innoviva (INVA) Q2 Sales Jump 64%
↗
August 06, 2025
Via
The Motley Fool
Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress
August 06, 2025
From
Innoviva, Inc.
Via
Business Wire
This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
July 14, 2025
Via
Benzinga
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
June 12, 2025
From
Innoviva Specialty Therapeutics, Inc.
Via
Business Wire
Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults
June 10, 2025
From
Innoviva, Inc.
Via
Business Wire
Innoviva to Participate in Upcoming Investor Conferences
June 03, 2025
From
Innoviva, Inc.
Via
Business Wire
ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections
May 20, 2025
From
Innoviva Specialty Therapeutics, Inc.
Via
Business Wire
Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress
May 07, 2025
From
Innoviva, Inc.
Via
Business Wire
Rep. George Whitesides Has Sold Up to $5.18M Worth Of Innoviva Stock: Here's What You Should Know
↗
April 24, 2025
Via
Benzinga
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
April 01, 2025
Via
Benzinga
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
March 05, 2025
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
February 26, 2025
From
Innoviva, Inc.
Via
Business Wire
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 06, 2025
From
Innoviva, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
